biote (NASDAQ:BTMD) Announces Earnings Results, Misses Expectations By $0.26 EPS

biote (NASDAQ:BTMD) posted its quarterly earnings data on Wednesday. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.26), FiscalAI reports. The firm had revenue of $44.23 million for the quarter, compared to analysts’ expectations of $46.12 million. biote had a negative return on equity of 25.72% and a net margin of 8.29%.

Here are the key takeaways from biote’s conference call:

• Negative Sentiment: Second-quarter revenue fell 9.5% to $44.2 million, while procedure revenue declined 13.9% to $30.3 million, pressured by the voluntary pellet recall, supply constraints, clinic attrition, and slower new-clinic productivity.
• Negative Sentiment: Biote lowered its 2026 outlook to revenue above $175 million and adjusted EBITDA above $25 million, compared with prior guidance of more than $190 million and $38 million, respectively; year-over-year procedure revenue is now expected to remain negative in the second half.
• Positive Sentiment: Management said Asteria Health’s supply continuity and inventory levels have normalized, with a second production shift added; reduced reliance on higher-cost third-party pellets is expected to improve gross margins beginning in the third quarter.
• Neutral Sentiment: The company is entering a second strategic phase focused on clinic retention, practitioner engagement, sales-force productivity, and faster new-clinic ramp-up, while also evaluating disciplined inorganic opportunities that could expand its market footprint.
• Positive Sentiment: Dietary-supplement revenue increased 5.7% to $11.4 million, supported by e-commerce and strong adoption among existing clinicians, and is expected to grow at a mid- to high-single-digit rate for 2026; recently resolved legal matters should also reduce future expenses.

biote Trading Down 0.4%

Shares of BTMD stock traded down $0.01 on Wednesday, reaching $2.26. 78,781 shares of the company’s stock were exchanged, compared to its average volume of 247,289. The company’s fifty day simple moving average is $2.22 and its 200 day simple moving average is $2.05. biote has a 52 week low of $1.27 and a 52 week high of $4.15. The stock has a market capitalization of $84.93 million, a PE ratio of 5.14 and a beta of 1.64.

Institutional Trading of biote

A number of hedge funds and other institutional investors have recently bought and sold shares of BTMD. Cubist Systematic Strategies LLC purchased a new stake in shares of biote during the first quarter valued at $76,000. AQR Capital Management LLC purchased a new position in biote in the 1st quarter worth about $43,000. Geode Capital Management LLC increased its stake in biote by 7.2% in the 2nd quarter. Geode Capital Management LLC now owns 616,697 shares of the company’s stock worth $2,480,000 after buying an additional 41,333 shares during the period. XTX Topco Ltd bought a new stake in biote during the 2nd quarter valued at about $68,000. Finally, First Trust Advisors LP lifted its holdings in biote by 5.3% during the 2nd quarter. First Trust Advisors LP now owns 73,669 shares of the company’s stock valued at $296,000 after buying an additional 3,675 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Truist Financial raised shares of biote to a “strong-buy” rating in a research note on Monday, June 15th. Weiss Ratings upgraded shares of biote from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, May 28th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $2.75.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.